Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Intern Emerg Med ; 16(5): 1165-1172, 2021 08.
Article Dans Anglais | MEDLINE | ID: covidwho-1074490

Résumé

The outbreak of coronavirus disease (COVID-19) has brought great challenges to the world. The objectives of this study were to describe the baseline characteristics and changes of biomarkers of these COVID-19 patients and identify predictive value of the above markers for patient death. Using patient death as the observational endpoints, clinical data of inpatients in a special ward for COVID-19 in Wuhan, China were retrospectively collected. Univariate and multivariate Cox regression analyses were used to evaluate prognostic value of baseline characteristics and laboratory data changes. This study included clinical data of 75 patients. Age, c-reactive protein (CRP) and interleukin-6 levels were independent predictors of patient death. Survivors were characterized as having declining neutrophil counts, D-dimer, N-terminal pronatriuretic peptide, troponin I (TnI) and c-reactive protein levels, while counts of lymphocyte gradually came back. Non-survivors were characterized with increasing white blood cell counts (WBC) and neutrophil counts. Changes of WBC, TnI and interleukin-6 were also independently associated with patient death. Older age, baseline CRP and IL-6 levels may be used as meaningful predictors to identify patients with poor prognosis. Changes of biomarkers should be closely monitored in the management of patients with COVID-19, while constantly increasing levels of WBC, TnI and interleukin-6 in the disease course also predict patient death.


Sujets)
Marqueurs biologiques/analyse , COVID-19/sang , COVID-19/mortalité , Adulte , Sujet âgé , Analyse de variance , Marqueurs biologiques/sang , Hémogramme/méthodes , Hémogramme/statistiques et données numériques , COVID-19/épidémiologie , Chine/épidémiologie , Évolution de la maladie , Femelle , Produits de dégradation de la fibrine et du fibrinogène/analyse , Humains , Lymphocytes/microbiologie , Mâle , Adulte d'âge moyen , Peptide natriurétique cérébral/analyse , Peptide natriurétique cérébral/sang , Granulocytes neutrophiles/microbiologie , Fragments peptidiques/analyse , Fragments peptidiques/sang , Pronostic , Modèles des risques proportionnels , Courbe ROC , Études rétrospectives , Troponine I/analyse , Troponine I/sang
3.
Appl Microbiol Biotechnol ; 104(18): 7777-7785, 2020 Sep.
Article Dans Anglais | MEDLINE | ID: covidwho-709732

Résumé

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel ß-coronavirus, is the main pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19). SARS-CoV-2 infects much more people, especially the elder population, around the world than other coronavirus, such as SARS-CoV and MERS-CoV, which is challenging current global public health system. Beyond the pathogenesis of SARS-CoV-2, microbial coinfection plays an important role in the occurrence and development of SARS-CoV-2 infection by raising the difficulties of diagnosis, treatment, prognosis of COVID-19, and even increasing the disease symptom and mortality. We summarize the coinfection of virus, bacteria and fungi with SARS-CoV-2, their effects on COVID-19, the reasons of coinfection, and the diagnosis to emphasize the importance of microbial coinfection in COVID-19. KEY POINTS: • Microbial coinfection is a nonnegligible factor in COVID-19. • Microbial coinfection exacerbates the processes of the occurrence, development and prognosis of COVID-19, and the difficulties of clinical diagnosis and treatment. • Different virus, bacteria, and fungi contributed to the coinfection with SARS-CoV-2.


Sujets)
Infections bactériennes/épidémiologie , Infections à coronavirus/épidémiologie , Syndrome de libération de cytokines/épidémiologie , Lymphopénie/épidémiologie , Mycoses/épidémiologie , Pandémies , Pneumopathie virale/épidémiologie , Maladies virales/épidémiologie , Antibactériens/usage thérapeutique , Antiviraux/usage thérapeutique , Infections bactériennes/traitement médicamenteux , Infections bactériennes/microbiologie , Infections bactériennes/virologie , Betacoronavirus/effets des médicaments et des substances chimiques , Betacoronavirus/immunologie , Betacoronavirus/pathogénicité , COVID-19 , Co-infection , Infections à coronavirus/traitement médicamenteux , Infections à coronavirus/microbiologie , Infections à coronavirus/virologie , Syndrome de libération de cytokines/traitement médicamenteux , Syndrome de libération de cytokines/microbiologie , Syndrome de libération de cytokines/virologie , Cytokines/biosynthèse , Évolution de la maladie , Interactions hôte-pathogène/immunologie , Humains , Immunité innée/effets des médicaments et des substances chimiques , Lymphocytes/microbiologie , Lymphocytes/virologie , Lymphopénie/traitement médicamenteux , Lymphopénie/microbiologie , Lymphopénie/virologie , Mycoses/traitement médicamenteux , Mycoses/microbiologie , Mycoses/virologie , Pneumopathie virale/traitement médicamenteux , Pneumopathie virale/microbiologie , Pneumopathie virale/virologie , SARS-CoV-2 , Maladies virales/traitement médicamenteux , Maladies virales/microbiologie , Maladies virales/virologie
SÉLECTION CITATIONS
Détails de la recherche